Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Maze Therapeutics, Inc.NASDAQ: MAZE
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns negative
Q1 FY2026 accounts receivables was -$20M, compared with $0 a year earlier. Trailing-twelve-month accounts receivables was -$20M.
Context
- Accounts receivables increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near -$20M or moves back toward the trailing-twelve-month quarterly average of -$5M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Accounts Receivables vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Accounts receivables amounts to 100.0% of revenue for MAZE, versus a peer median of 6.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $44.38M USD | -720.6% | -40.6% | 4.4% | |
| LTM Mar 2026 | $36.37M USD | +98.7% | +25.1% | 8.5% | |
| LTM Mar 2026 | $20M USD | — | — | 100.0% | |
| LTM Sep 2026 | $13.84M USD | -76.0% | +168.7% | 2.1% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $10.24M USD | +21.4% | — | 10.6% |
| FY2025 | €816.45K EUR | -70.9% | -40.3% | 18.2% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $348K USD | -3.6% | — | 3.4% |
| LTM Mar 2026 | $49.73K USD | -134.1% | — | — | |
| Peer median (excluding MAZE) | — | -70.9% | -7.6% | 6.5% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.